Abstract
Peptides are recognized as highly promising
therapeutics due to their high selectivity, efficacy, and safety. Enormous
research development efforts have been devoted to developing peptide
therapeutics, and more than 170 peptides therapeutics are currently being evaluated in
clinical trials. However, the major drawback of peptide therapeutics is their short
plasma half-life. Dr. Moon has developed linker peptides/proteins
for intracellularly delivering small molecules such as drugs, nucleic acids,
and peptides, as well as proteins and other larger molecules. These linker
peptides/proteins are made of plurality of oligo( amino acid)s or poly( amino
acid)s, where the acid residues can bear one or more positively charged
guanylurea units. Many hydrophilic or
hydrophobic functional groups can then be introduced at the units via guanylurea
chemistry to modulate the linker peptides/proteins properties. Their C and N terminals can also be functionalized
with small molecules such as drugs, antibodies, targeting moieties, detectable
entities, further tailoring the linker peptides/proteins to specific needs.
Benefit
Enhanced blood circulation time and peptide serum stabilityEnhanced intracellular drug delivery and specific targeting, and pharmacokinetics
Market Application
Drug deliveryDrug development
Brochure
